Page 4 - Johnson Middle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TIMMONSVILLE, S.C. (AP) — Two school board members of a district taken over by South...

D.C. Public Schools (DCPS) officials are urging parents to add COVID-19 vaccinations to the list of things students need to start school in the fall. They’ve...

Brevard's Official At Work Station!

Janssen’s Erleada maintains quality of life for prostate cancer patients 27th May 2021 Janssen’s Erleada in addition to androgen deprivation therapy (ADT) maintained prostate cancer patients’ health-related quality of life (HRQoL), according to new patient-reported outcomes (PRO) data. The PRO data from the prespecified final analysis of the Phase III TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) also showed that the addition of Erleada (apalutamide) to ADT did not worse side effect burden. In both treatment groups – patients who received Erleada pl...

Janssen’s Erleada improves survival in certain advanced prostate cancer patients Final analysis demonstrates a 35% reduction in the risk of death in mHSPC patients The final analysis of Janssen’s phase 3 TITAN study has demonstrated continued overall survival (OS) benefit of Erleada plus androgen deprivation therapy (ADT) in certain prostate cancer patients. The TITAN study evaluated Erleada (apalutamide) plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to placebo plus ADT. The new data, which includes nearly four years of median follow-up, demonstr...